286 related articles for article (PubMed ID: 30528935)
1. Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report.
Liou AA; Skiver BM; Yates E; Persad P; Meyer D; Farland AM; Rocco MV
Am J Kidney Dis; 2019 May; 73(5):615-619. PubMed ID: 30528935
[TBL] [Abstract][Full Text] [Related]
2. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
[TBL] [Abstract][Full Text] [Related]
3. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Nishikubo M; Shimomura Y; Hiramoto N; Sawamura N; Yamaguchi T; Hara S; Ishikawa T
BMC Nephrol; 2021 May; 22(1):175. PubMed ID: 33980166
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease.
Bourdin V; Fossé Q; Lambotte O; Joly B; Coppo P; Anguel N; Labeyrie C
Br J Haematol; 2024 Apr; 204(4):1459-1463. PubMed ID: 38112161
[TBL] [Abstract][Full Text] [Related]
5. Quinine-Induced Thrombotic Microangiopathy: A Report of 19 Patients.
Page EE; Little DJ; Vesely SK; George JN
Am J Kidney Dis; 2017 Nov; 70(5):686-695. PubMed ID: 28780041
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic microangiopathy and acute kidney injury following vivax malaria.
Sinha A; Singh G; Bhat AS; Mohapatra S; Gulati A; Hari P; Samantaray JC; Dinda AK; Agarwal SK; Bagga A
Clin Exp Nephrol; 2013 Feb; 17(1):66-72. PubMed ID: 22752395
[TBL] [Abstract][Full Text] [Related]
7. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure.
Ali A; Schlanger L; Nasr SH; Sethi S; Gorbatkin SM
Am J Kidney Dis; 2016 Mar; 67(3):479-82. PubMed ID: 26704376
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer.
Morimoto M; Arai T; Matsuura M; Ono Y
CEN Case Rep; 2021 Feb; 10(1):6-11. PubMed ID: 32642991
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report.
Broughton A; Cosyns JP; Jadoul M
Clin Nephrol; 2011 Nov; 76(5):396-400. PubMed ID: 22000560
[TBL] [Abstract][Full Text] [Related]
10. Kidney Biopsy Proven Thrombotic Microangiopathy Induced by Methamphetamine.
Nagaoka K; Katagiri D; Matsunami M; Chinen M; Seki K; Fukuda J; Ohara M; Suzuki T
Intern Med; 2024 Jun; 63(11):1603-1608. PubMed ID: 37866922
[TBL] [Abstract][Full Text] [Related]
11. Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus.
Sprangers B; Decoo D; Dive D; Lysandropoulos A; Vanopdenbosch L; Bovy C
Acta Neurol Belg; 2018 Jun; 118(2):143-151. PubMed ID: 29189966
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
Alamo A; Condorelli RA; La Vignera S; Calogero AE
Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic microangiopathy caused by oral contraceptives in a kidney transplant recipient.
Shirai H; Yashima J; Tojimbara T; Honda K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():41-3. PubMed ID: 26970708
[TBL] [Abstract][Full Text] [Related]
14. Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA.
Yazaki K; Sakuma S; Hikita N; Fujimaru R; Hamazaki T
Neurology; 2022 May; 98(19):808-813. PubMed ID: 35351784
[TBL] [Abstract][Full Text] [Related]
15. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.
Mahe J; Meurette A; Moreau A; Vercel C; Jolliet P
Drug Des Devel Ther; 2013; 7():723-8. PubMed ID: 23950639
[TBL] [Abstract][Full Text] [Related]
16. De Novo Thrombotic Microangiopathy Immediately After Kidney Transplant in Patients Without Apparent Risk Factors.
Patel A; Knorr JP; Campos S; Khanmoradi K; Zaki RF; Bradauskaite G
Exp Clin Transplant; 2016 Apr; 14(2):230-4. PubMed ID: 26030297
[TBL] [Abstract][Full Text] [Related]
17. A case of thrombotic microangiopathy associated with polymyositis.
Fukuda M; Mizuno H; Hiramatsu R; Sekine A; Kawada M; Hasegawa E; Yamanouchi M; Suwabe T; Hoshino J; Sawa N; Takaichi K; Kinowaki K; Ohashi K; Fujii T; Miyazono M; Ubara Y
Clin Nephrol; 2021 Jun; 95(6):339-344. PubMed ID: 33769275
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
Aitken L; Patel R; D'Rozario J; Choi P
Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
[TBL] [Abstract][Full Text] [Related]
19. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
20. Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.
Cassol CA; Williams MPA; Caza TN; Rodriguez S
Medicine (Baltimore); 2019 Sep; 98(39):e17148. PubMed ID: 31574818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
